中国少妇大P毛茸茸

Ningbo Kunpeng Biotech Co., Ltd. was established in April 2016. The company takes "providing medicines, technologies and services for human disease control" as its mission and is committed to the research, development, production and sales of human drugs. In the field of diabetes treatment drugs, the company has developed a product including recombinant human insulin, insulin glargine, insulin aspart, liraglutide and other pharmaceutical products using the unique "protein fixed-point modification technology" platform and subversive process engineering technology development. chain. At the same time, research on new drugs such as new long-acting insulin and GLP-1 analogs is also actively underway. The company has a complete R&D and pilot test platform, and has formed a team of R&D, production and quality management talents including several domestic and foreign technical experts. In the first phase of industrialization, RMB 200 million Details>>